To read the full story, subscribe or sign in.

Gilead ends $785M Yuhan deal for small-molecule MASH drugs

Oct. 15, 2024

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.

BioWorld Asia Deals and M&A License Endocrine/metabolic Gastrointestinal Small molecule Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for Nov. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 2, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

Apollo signs near-$1B deal for Sunshine’s FGF21/GLP-1 injection

BioWorld Asia

Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual...

Upgrade your daily dose of biopharma and medtech news

Gilead ends $785M Yuhan deal for small-molecule MASH drugs